The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, multicenter, open-label, blinded-endpoint Phase III
clinical trial to investigate the impact of thromboprophylaxis using innohep, beyond
anticoagulation in the improvement of the clinical outcomes in active prostate cancer
patients receiving systemic anti-neoplasmatic treatment. The number of patients that will be
enrolled is 450. The enrollment period is 24 months and the follow up period is 10 months.